Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis

Modern Rheumatology

Volumn 24, Issue 4, 2014, Pages 618-625

  Ikeuchi, Hidekazu ^a   Hiromura, Keiju ^a   Takahashi, Satoshi ^a   Mishima, Keiichiro ^a   Sakurai, Noriyuki ^a   Sakairi, Toru ^a   Kaneko, Yoriaki ^a   Maeshima, Akito ^a   Kuroiwa, Takashi ^a   Nojima, Yoshihisa ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunosuppressive therapy; Lupus nephritis; Multi target therapy; Mycophenolate mofetil; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTON PUMP INHIBITOR; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ABDOMINAL SKIN ULCER; ADULT; ANTIVIRAL THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CREATININE URINE LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL FUNGAL INFECTION; FEMALE; HOSPITAL DEPARTMENT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INTENTION TO TREAT ANALYSIS; KIDNEY DYSFUNCTION; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; LUPUS NEPHRITIS; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903696731     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844397     Document Type: Article

References (34)

1. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006;70(8):1403-12.
2. Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM. 2001;94(1):19-26.
3. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus-what's hot and what's not! Rheumatology (Oxford). 2009;48(4):332-41.
4. Steinberg AD. The treatment of lupus nephritis. Kidney Int. 1986; 30(5):769-87.
5. Gourley MF, Austin HA IIIrd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549-57.
6. Boumpas DT, Austin HA IIIrd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741-5.
7. Ntali S, Bertsias G, Boumpas DT. Cyclophosphamide and lupus nephritis: when, how, for how long? Clin Rev Allergy Immunol. 2011;40(3):181-91.
8. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diff use proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156-62.
9. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219-28.
10. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology. 2005;10(5):504-10.
11. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12.
12. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007; 2(5):968-75.
13. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808.
14. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerul-onephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Chapter 12: Lupus nephritis. Kidney Int Suppl. 2012;2:221-32.
15. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71(11): 1771-82.
16. Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19:1281-9.
17. Chen W, Tang X, Liu Q, Fu P, Liu F, Liao Y, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44.
18. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4): 1467-72.
19. Takahashi S, Hiromura K, Sakurai N, Matsumoto T, Ikeuchi H, Maeshima A, et al. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol. 2011;21(3):282-9.
20. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+ IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001-10.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630-40.
23. Li H, Shi X, Shen H, Li X, Wang H, Xu G, et al. Tacrolimus versus intravenous pulse cyclophosphamide therapy in chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Clinical therapeutics. 2012; 34(5): 1112-20.
24. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64(11):3660-5.
25. Najai CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59(6):2156-63.
26. Holdsworth SR, Kitching AR, Tipping PG Th1 and Th2 T helper cell subsets aff ect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 1999;55(4):1198-216.
27. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol. 1999;10(6):1366-80.
28. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs Today (Barc). 2009;45(7):521-32.
29. Kagawa H, Hiromasa T, Hara T, Takaki A, Yamanaka R, Sada KE, Makino H. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol. 2012;16(5):760-6.
30. Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus. 2012;21(13):1444-9.
31. Kawasaki Y Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009:681482.
32. Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?-A mini-review. Braz J Infect Dis. 2006;10(2):132-8.
33. Falk RJ, Schur PH, Appel GB. Indications for renal biopsy in patients with lupus nephritis. In: UpToDate, Sheridan AM, editor. Waltham: MA; 2009.
34. Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol. 2000;27(12):2822-6.